Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,401–1,500 of 4,275
Impact of aging on bone, marrow and their interactions
Hoffman, C. M., Han, J., & Calvi, L. M. (2018) · Bone · doi:10.1016/j.bone.2018.07.012 · Cited by 49
Chin, A. F., Han, J., Clement, C. C., Choi, Y., Zhang, H., Browne, M., Jeon, O. H., & Elisseeff, J. H. (2023) · Aging Cell · doi:10.1111/acel.13979 · Cited by 46
Pancreatic β-cell senescence in diabetes: mechanisms, markers and therapies
Cha, J., Aguayo‐Mazzucato, C., & Thompson, P. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1212716 · Cited by 54
Toward a Unified Theory of Aging and Regeneration
West, M. D., Sternberg, H., Labat, I., Janus, J., Chapman, K. B., Malik, N. N., de Grey, A. D. N. J., & Larocca, D. (2019) · Regenerative Medicine · doi:10.2217/rme-2019-0062 · Cited by 50
Zhang, L., Guan, Q., Wang, Z., Feng, J., Zou, J., & Gao, B. (2023) · Aging and Disease · doi:10.14336/ad.2023.1115 · Cited by 89
“IL-1α IL-1α/β, IL-6 and IL-8 are proinflammatory factors that can activate SASP [369-371] .”
Du, M., Sun, L., Guo, J. J., & Lv, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107198 · Cited by 57
Inflammaging, cellular senescence, and cognitive aging after traumatic brain injury
Lu, Y., Jarrahi, A., Moore, N. D., Bartoli, M., Brann, D. W., Baban, B., & Dhandapani, K. M. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106090 · Cited by 54
“SASP consists of increased, cell-dependent secretion of interleukins, cytokines, chemokines, and matrix metalloproteinases to potentiate senescence and perpetuate inflammaging (Coppe et al., 2008; Kuilman and Peeper, 2009).”
BackgroundMechanisms driving the ageing heart
Anderson, R., Richardson, G. D., & Passos, J. F. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.10.015 · Cited by 46
“On a non-cell-autonomous level, a hallmark of cellular senescence is the induction of a proinflammatory secretome, known as the Senescence-Associated Secretory Phenotype (SASP) which involves the secretion of a number of factors, such as interleukins and inflammatory cytokines, into the extra-cellular environment (Cop…”
Taschner‐Mandl, S., Schwarz, M., Blaha, J., Kauer, M. O., Kromp, F., Frank, N., Rifatbegovic, F., Weiss, T., Ladenstein, R. L., HOHENEGGER, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6527 · Cited by 49
Senescence gives insights into the morphogenetic evolution of anamniotes
Villiard, É., Denis, J.-F., Hashemi, F. S., Igelmann, S., Ferbeyre, G., & Roy, S. (2017) · Biology Open · doi:10.1242/bio.025809 · Cited by 46
“Other genes associated with SASP were assessed as interleukin (IL)-10, -8, -6 and Amphiregulin (AREG) (Coppé et al., 2008).”
Dash, S., Sahu, A. K., Srivastava, A., Chowdhury, R., & Mukherjee, S. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155348 · Cited by 49
Aging per se Increases the Susceptibility to Free Fatty Acid-Induced Insulin Resistance
Einstein, F. H., Huffman, D. M., Fishman, S., Jerschow, E., Heo, H. J., Atzmon, G., Schechter, C., Barzilai, N., & Muzumdar, R. H. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq078 · Cited by 46
“Furthermore, other biologic changes may also be responsible for heightened inflammation with aging such as declines in sex steroids (37,38) and increased prevalence of senescent cells, which have been shown to have a proinflammatory secretory phenotype (39) and can accumulate in metabolically relevant tissues with agi…”
BackgroundThe paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan, E. A., Wallis, R., Mossa, F., & Bishop, C. L. (2024) · npj Aging · doi:10.1038/s41514-024-00168-y · Cited by 62
Cancer and Cardiovascular Disease
Alhuneafat, L., Guha, A., Blaes, A. H., & Konety, S. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.07.001 · Cited by 66
Involvement of stromal p53 in tumor-stroma interactions
Bar, J., Moskovits, N., & Oren, M. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.11.006 · Cited by 46
“Senescent fibroblasts were found to secrete a plethora of proteins, whose collective effect led to enhanced invasion and epithelial-to-mesenchymal transition (EMT) of cancer cells [28].”
BackgroundMicroglia Phenotypes Converge in Aging and Neurodegenerative Disease
Candlish, M., & Hefendehl, J. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.660720 · Cited by 51
Ijima, S., Saito, Y., Nagaoka, K., Yamamoto, S., Sato, T., Miura, N., Iwamoto, T., Miyajima, M., & Chikenji, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960601 · Cited by 50
“PCR analysis showed that fisetin treatment decreased the expression of senescence-related genes (Cdkn1a, Cdkn2a (p16 and p19), and Cdkn2b), SASPrelated genes (Tnf, Mmp3, Il1b, Tgfb1, and Il6), and fibrosisrelated genes (Col1a1, Col3a1, Fn1, Mki67, Acta2, and Vim) (Figure 5L).”
BackgroundInfluentialHan, L., Xu, J., Xu, Q. R., Zhang, B., Lam, E. W. ‐., & Sun, Y. (2017) · Medicinal Research Reviews · doi:10.1002/med.21453 · Cited by 47
Self-citationFZD5 regulates cellular senescence in human mesenchymal stem/stromal cells
Harada, S., Mabuchi, Y., Kohyama, J., Shimojo, D., Suzuki, S., Kawamura, Y., Araki, D., Suyama, T. L., Kajikawa, M., Akazawa, C., et al. (2020) · Stem Cells · doi:10.1002/stem.3317 · Cited by 50
Senescent cells limit p53 activity via multiple mechanisms to remain viable
Sturmlechner, I., Sine, C. C., Jeganathan, K. B., Zhang, C., Fierro Velasco, R. O., Baker, D. J., Li, H., & van Deursen, J. M. (2022) · Nature Communications · doi:10.1038/s41467-022-31239-x · Cited by 45
Pungsrinont, T., Sutter, M. F., Ertingshausen, M. C. C. M., Lakshmana, G., Kokal, M., Khan, A. S., & Baniahmad, A. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00422-2 · Cited by 47
Major depression and enhanced molecular senescence abnormalities in young and middle-aged adults
Diniz, B. S., Reynolds III, C. F., Sibille, E., Bot, M., & Penninx, B. W. J. H. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0541-3 · Cited by 45
Qin, Z., Gu, X., Chen, Y., Liu, J., Hou, C.-X., Lin, S., Hao, N., Liang, Y., Chen, W., & Meng, H. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4787 · Cited by 46
“Senescent fibroblasts have been hypothesized to express high levels of SASP factors, and exhibit higher expression of biologically active TLR4 compared with other cells in diseased periodontal tissues (17,18).”
BackgroundMenicacci, B., Laurenzana, A., Chillà, A., Margheri, F., Peppicelli, S., Tanganelli, E., Fibbi, G., Giovannelli, L., Del Rosso, M., & Mocali, A. (2017) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glw336 · Cited by 47
Chung, E. J., McKay-Corkum, G. B., Chung, S. I., White, A. O., Scroggins, B. T., Mitchell, J. B., Mulligan‐Kehoe, M. J., & Citrin, D. E. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.11.044 · Cited by 48
“Aside from its role in senescence, PAI-1 has been described as a component of the SASP, a group of molecules secreted by senescent cells, many of which are pro-inflammatory and mitogenic in nature (17,29,30,52).”
c-Myc Is Essential to Prevent Endothelial Pro-Inflammatory Senescent Phenotype
Florea, V., Bhagavatula, N., Simovic, G., Macedo, F., Fock, R. A., & Rodrigues, C. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073146 · Cited by 51
Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers
Zacarias-Fluck, M. F., Morancho, B., Vicario, R., Luque Garcia, A., Escorihuela, M., Villanueva, J., Rubio, I. T., & Arribas, J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv020 · Cited by 45
Elimination of p19ARF‐expressing cells protects against pulmonary emphysema in mice
Mikawa, R., Suzuki, Y., Baskoro, H., Kanayama, K., Sugimoto, K., Sato, T., & Sugimoto, M. (2018) · Aging Cell · doi:10.1111/acel.12827 · Cited by 45
“In addition to cell proliferation arrest, it is now evident that senescent cells secrete many pro‐inflammatory factors, proteinases, and other bioactive substances (Coppé et al., 2008).”
BackgroundAn ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis
Abe, J., Imanishi, M., Li, S., Zhang, A., Ko, K. A., Samanthapudi, V. S. K., Lee, L.-L., Paniagua-Bojorges, A., Gi, Y. J., Hobbs, B. P., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.322017 · Cited by 48
A tale of the good and bad: Cell senescence in bone homeostasis and disease
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.03.005 · Cited by 45
Lewińska, A., Przybylski, P., Adamczyk‐Grochala, J., Błoniarz, D., Litwinienko, G., & Wnuk, M. (2022) · Cancers · doi:10.3390/cancers14030605 · Cited by 55
“As cellular senescence is characterized by senescence-associated secretory phenotype (SASP) [3,4], we have also evaluated the levels of selected proinflammatory factors such as IL-1β and IL-8 (Figure 3).”
BackgroundLife and death of microglia: Mechanisms governing microglial states and fates
Matsudaira, T., & Prinz, M. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.04.001 · Cited by 49
Irradiation Alters Selection for Oncogenic Mutations in Hematopoietic Progenitors
Marusyk, A., Casás‐Selves, M., Henry, C. J., Zaberezhnyy, V., Klawitter, J., Christians, U., & DeGregori, J. V. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0604 · Cited by 49
“Irradiation-induced senescence of fibroblasts dramatically boosts cytokine production (41, 42), which could be envisioned to promote tumorigenesis either by selective pro-proliferative effects of cytokines on initiated cells or by selectively impairing the fitness of noninitiated cells.”
BackgroundCircumventing senescence is associated with stem cell properties and metformin sensitivity
Deschênes‐Simard, X., Parisotto, M., Rowell, M., Le Calvé, B., Igelmann, S., Moineau‐Vallée, K., Saint‐Germain, E., Kalegari, P., Bourdeau, V., Kottakis, F., et al. (2019) · Aging Cell · doi:10.1111/acel.12889 · Cited by 45
“These genes are often upregulated in senescent cells as part of the senescence‐associated secretory phenotype (SASP; Coppe et al., 2008).”
BackgroundReimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas
Milde, T., Rodriguez, F. J., Barnholtz‐Sloan, J. S., Patil, N. T., Eberhart, C. G., & Gutmann, D. H. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab138 · Cited by 48
Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis
Pavlakis, E., Neumann, M. M., & Stiewe, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249648 · Cited by 47
“For example, the p53-mediated regulation of numerous genes encoding for secreted proteins enforces cellular senescence, a tumor-suppressive cellular program that involves stable proliferative arrest and microenvironmental alterations in a non-cell autonomous manner [19].”
BackgroundZhu, D., Deng, X., Xu, J., & Hinton, D. R. (2009) · Aging · doi:10.18632/aging.100078 · Cited by 45
“IL-8 promotes angiogenesis by increasing the proliferation, survival and migration of endothelial cells and promotes inflammation by increasing neutrophil chemotaxis and degranulation [29-31].”
BackgroundInduction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53
Quinn, B. A., Brake, T., Xiang, H., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008404 · Cited by 48
“Interestingly, recent work showed that cells exhibiting a senescence associated secretory phenotype (SASP) contribute to epithelial to mesenchymal transitions and invasiveness in a cell non-autonomous manner, with inactivation of p53 being a major contributor to these pro-malignant paracrine activities [49].”
Backgroundp53-Dependent Induction of Prostate Cancer Cell Senescence by the PIM1 Protein Kinase
Zemskova, M., Lilly, M. B., Lin, Y.-W., Song, J. H., & Kraft, A. S. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0174 · Cited by 48
Cellular senescence: friend or foe to respiratory viral infections?
Kelley, W. J., Zemans, R. L., & Goldstein, D. R. (2020) · European Respiratory Journal · doi:10.1183/13993003.02708-2020 · Cited by 45
Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis
Nakahara, Y., Hashimoto, N., Sakamoto, K., Enomoto, A., Adams, T. S., Yokoi, T., Omote, N., Poli, S., Ando, A., Wakahara, K., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03397-2020 · Cited by 49
The End and After: How Dying Cells Impact the Living Organism
Green, D. R. (2011) · Immunity · doi:10.1016/j.immuni.2011.10.003 · Cited by 48
“Such cells, like dying cells, are cleared from the body and produce mediators that facilitate such clearance (e.g., Coppé et al., 2008).”
BackgroundThe role of cellular senescence in aging through the prism of Koch-like criteria
Yanai, H., & Fraifeld, V. E. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.10.004 · Cited by 45
Oxidative stress-induced senescence markedly increases disc cell bioenergetics
Patil, P. R., Falabella, M., Saeed, A., Lee, D., Kaufman, B. A., Shiva, S., Croix, C. M. S., Houten, B. V., Niedernhofer, L. J., Robbins, P. D., et al. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.04.006 · Cited by 46
Oncogenic senescence: a multi-functional perspective
Baker, D. J., Alimirah, F., van Deursen, J. M., Campisi, J., & Hildesheim, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15742 · Cited by 45
Self-citationFausti, F., Agostino, S. D., Cioce, M., Bielli, P., Sette, C., Pandolfi, P. P., Oren, M., Sudol, M., Strano, S., & Blandino, G. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.101 · Cited by 53
“Senescent cells release a plethora of cytokines and pro-mitogenic factors and this process is called SASP.(14,15)”
BackgroundInfluentialMechanisms involved in hematopoietic stem cell aging
Fujino, T., Asada, S., Goyama, S., & Kitamura, T. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04356-5 · Cited by 56
“Proinflammatory cytokines are SASP factors that are secreted by senescent cells.”
BackgroundInfluentialTargeting senescence to delay progression of multiple sclerosis
Oost, W., Talma, N., Meilof, J. F., & Laman, J. D. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1686-x · Cited by 49
Guo, Z., Zhang, Y., Gong, Y., Li, G., Pan, J., Dou, D., Ma, K., Cui, C., Liu, Y., & Zhu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.029 · Cited by 53
Cellular Senescence, Neurological Function, and Redox State
Maciel-Barón, L. Á., Moreno-Blas, D., Morales-Rosales, S. L., González-Puertos, V. Y., López-Díazguerrero, N. E., Torres, C., Castro-Obregón, S., & Königsberg, M. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7112 · Cited by 45
“Cellular senescence is accompanied by the secretion of a diverse array of molecules such as cytokines, chemo-kines, growth factors, and proteases among others, known as senescence-associated secretory phenotype (SASP) (2, 25, 89), which has pleiotropic effects that will be discussed later.”
InfluentialBCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human Centenarians
Borrás, C., Mas‐Bargues, C., Román-Domínguez, A., Sanz‐Ros, J., Gimeno-Mallench, L., Inglés, M., Gambini, J., & Viña, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020418 · Cited by 50
“It is well known that senescent cells tend to accumulate with age in multiple organisms provoking deleterious effects in neighboring cells and tissues, mainly due to senescence-associated secretory phenotype (SASP) [81].”
BackgroundThe Senescence-Associated Secretory Phenotype Promotes Benign Prostatic Hyperplasia
Vital, P., Castro, P. D., Tsang, S. V., & Ittmann, M. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.11.015 · Cited by 45
“10,11 This phenomenon is known as the senescence-associated secretory phenotype.”
BackgroundGiuliano, S., Dufies, M., Ndiaye, P. D., Viotti, J., Borchiellini, D., Parola, J., Vial, V., Cormerais, Y., Ohanna, M., Imbert, V., et al. (2019) · Theranostics · doi:10.7150/thno.29093 · Cited by 47
“Their release into the tumor microenvironment stimulated the proliferation of cancer cells, as well as epithelial to mesenchymal transition (EMT) and angiogenesis therefore resulting in accelerated dissemination of metastasis [45, 46].”
BackgroundIntervertebral disc cell fate during aging and degeneration: apoptosis, senescence, and autophagy
Yurube, T., Takeoka, Y., Kanda, Y., Kuroda, R., & Kakutani, K. (2023) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2023.100210 · Cited by 66
Pawlikowski, J. S., Adams, P. D., & Nelson, D. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.109728 · Cited by 70
“…by senescent cells can also facilitate detrimental non-cell-autonomous effects, including enhancement of cell growth, induction of the epithelial-to-mesenchymal transition (EMT) and invasiveness and the promotion of tumorigenesis (Coppé et al., 2008; Krtolica et al., 2001; Yoshimoto et al., 2013).”
BackgroundA reciprocal role of prostate cancer on stromal DNA damage
Banerjee, J., Mishra, R., Li, X., Jackson, R. S., Sharma, A., & Bhowmick, N. A. (2013) · Oncogene · doi:10.1038/onc.2013.431 · Cited by 45
“Intriguingly, the epigenetic loss of TGFBR2 expression in prostatic fibroblasts, initiated by interactions with PCa (Figure 1), results in the promoter methylation and silencing of DNA damage repair mediators (12, 18, 24).”
InfluentialThompson, P. J., Shah, A. N., Apostolopolou, C.-C., & Bhushan, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194776 · Cited by 47
“SASP is controlled at multiple levels, including the level of chromatin and transcription [4,5].”
BackgroundCirillo, N., Hassona, Y. M., Celentano, A., Lim, K. P., Manchella, S., Parkinson, E. K., & Prime, S. S. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw113 · Cited by 44
“It is now well established that senescent fibroblasts, generated as a result of replication, oncogenic stress or oxidative DNA damage, induce EMT in breast cancer cell lines (10).”
InfluentialCellular Senescence as a Target in Cancer Control
Vergel, M., Marin, J. J., Estevez, P., & Carnero, A. (2011) · Journal of Aging Research · doi:10.4061/2011/725365 · Cited by 44
Karaayvaz, M., Silberman, R. E., Langenbucher, A., Saladi, S. V., Ross, K. N., Zarcaro, E., Desmond, A. J., Yıldırım, M., Vivekanandan, V., Ravichandran, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay2611 · Cited by 45
Senescence as a dictator of patient outcomes and therapeutic efficacies in human gastric cancer
Zhou, L., Niu, Z., Wang, Y., Zheng, Y. Y., Zhu, Y., Wang, C., Gao, X., Gao, L., Zhang, W., Zhang, K., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00769-6 · Cited by 47
Zhang, J., Zhang, S., Song, J., Sun, K., Zong, C., Zhao, Q., Liu, W., Li, R., Wu, M., & Wei, L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.009 · Cited by 45
Hyaluronan: A key player or just a bystander in skin photoaging?
Šínová, R., Pavlík, V., Ondrej, M., Velebný, V., & Nešporová, K. (2021) · Experimental Dermatology · doi:10.1111/exd.14491 · Cited by 47
Lin, W., Wang, X., Wang, Z., Shao, F., Yang, Y., Cao, Z., Feng, X., Gao, Y., & He, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.780461 · Cited by 51
Vassilieva, I. O., Kosheverova, V., Vitte, M. A., Kamentseva, R., Shatrova, A. N., Цупкина, Н. В., Skvortsova, E. V., Borodkina, A. V., Tolkunova, E. N., Nikolsky, N. N., et al. (2020) · Aging · doi:10.18632/aging.102737 · Cited by 50
Maï, M. E., Marzullo, M., de Castro, I. P., & Ferreira, M. G. (2020) · eLife · doi:10.7554/elife.54935 · Cited by 52
“Inefficient removal of senescent cells results in their accumulation and persistent SASP production.”
InfluentialFunctional genomics of inflamm-aging and immunosenescence
Lu, R. J., Wang, E. K., & Benayoun, B. A. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab009 · Cited by 46
Secretome of Human Fetal Mesenchymal Stem Cell Ameliorates Replicative Senescence
Wang, B., Lee, W., Huang, B., Zhang, J., Wu, T., Jiang, X., Wang, C. C., & Li, G. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0079 · Cited by 50
Dynamic Crosstalk between Vascular Smooth Muscle Cells and the Aged Extracellular Matrix
Ribeiro-Silva, J. C., Nolasco, P., Krieger, J. E., & Miyakawa, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810175 · Cited by 59
“Senescent SMC exhibits the secretory phenotype (SASP) [142] and microRNA-203 [181] upregulation may decrease the expression of structural elements such as vinculin and partially blunt SMC viscoelasticity (culminating in ROCK-mediated increased stiffness, but reduction of contractility) and the ability to regenerate th…”
BackgroundInfluentialŠalovská, B., Kondelová, A., Pimková, K., Liblova, Z., Přibyl, M., Fabrik, I., Bártek, J., Vajrychová, M., & Hodný, Z. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102212 · Cited by 56
After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation
Fletcher, J. S., Pundavela, J., & Ratner, N. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz045 · Cited by 54
Jones, T. A., Jeyapalan, J. N., Forshew, T., Tatevossian, R., Lawson, A. R. J., Patel, S. N., Doctor, G. T., Mumin, M., Picker, S. R., Phipps, K. P., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0266-3 · Cited by 48
“regulation of IL1B, which has been shown to be a SASP-associated protein [10].”
Alexander, E., Hildebrand, D. G., Kriebs, A., Obermayer, K., Manz, M., Rothfuss, O., Essmann, F., & Schulze-Osthoff, K. (2013) · Journal of Cell Science · doi:10.1242/jcs.128835 · Cited by 44
“In addition, it has been identified that senescent cells secrete a number of growth and immune factors, a feature termed senescence-associated secretory phenotype (SASP) or senescence-messaging secretome (Coppé et al., 2008; Coppé et al., 2010; Kuilman and Peeper, 2009).”
BackgroundSilva, G. C., Abbas, M., Khemais-Benkhiat, S., Burban, M., Ribeiro, T. P., Toti, F., Idris-Khodja, N., Côrtes, S. F., & Schini-Kerth, V. B. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.04.006 · Cited by 44
IL-1/IL-1R Signaling in Head and Neck Cancer
Niklander, S. E., Murdoch, C., & Hunter, K. D. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.722676 · Cited by 47
“These findings strongly suggest a role of IL-1β in EMT in OSCC [98], which has also been reported by Frontiers in Oral Health | www.frontiersin.org 5 August 2021 | Volume 2 | Article 722676 FIGURE 2 | Comparison of IL-1α expression and regulation in normal head and neck keratinocytes (A) and in cancerous head and neck…”
BackgroundInfluentialGuo, S., Fu, L., Yin, C., Shao, W., Sun, Q., Chen, L., Xia, T., Wang, M., & Xia, H. (2024) · Inflammation · doi:10.1007/s10753-024-02014-5 · Cited by 53
“Senescent cells could contribute to chronic low-grade systemic inflammation via secreting pro-inflammatory cytokines, chemokines, growth factors, and metalloproteinases, collectively known as senescence-associated secretory phenotype (SASP) [11].”
Liu, D., Richardson, G. D., Benli, F. M., Park, C., de Souza, J. V. B., Bronowska, A. K., & Spyridopoulos, I. (2020) · Clinical Science · doi:10.1042/cs20191213 · Cited by 51
Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases
Ruíz, A., Flores‐González, J., Buendía-Roldán, I., & Chávez‐Galán, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010425 · Cited by 49
“But, on the other hand, it can affect surrounding cells or neighboring tissues, promoting a tumoral effect [16,17].”
BackgroundMechanistic complexities of bone loss in Alzheimer’s disease: a review
Frame, G., Bretland, K. A., & Dengler-Crish, C. M. (2020) · Connective Tissue Research · doi:10.1080/03008207.2019.1624734 · Cited by 44
Cellular senescence in cancer: molecular mechanisms and therapeutic targets
Jin, P., Duan, X., Li, L., Zhou, P., Zou, C., & Xie, K. (2024) · MedComm · doi:10.1002/mco2.542 · Cited by 57
Early aging and premature vascular aging in chronic kidney disease
Tanrıöver, C., Çöpür, S., Mutlu, A., Peltek, İ. B., Galassi, A., Ciceri, P., Cozzolino, M. G., & Kanbay, M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad076 · Cited by 53
“SASP is characterized by increased expression and secretion of growth factors, cytokines, proteases, and chemokines [33].”
BackgroundInhibition of glutaminolysis restores mitochondrial function in senescent stem cells
Choudhury, D., Rong, N., Ikhapoh, I. A., Rajabian, N., Tseropoulos, G., Wu, Y., Mehrotra, P., Thiyagarajan, R., Shahini, A., Seldeen, K. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111744 · Cited by 47
O’Hara, S. P., Splinter, P. L., Trussoni, C. E., Guicciardi, M. E., Splinter, N. P., Alsuraih, M., Nasser‐Ghodsi, N., Stollenwerk, D., Gores, G. J., & LaRusso, N. F. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010176 · Cited by 43
“Senescent cells frequently transition to the senescence-associated secretory phenotype (SASP), a potentially pathologic state of proinflammatory cytokine, chemokine, and growth factor hypersecretion [15].”
BackgroundAdipose tissue immune cells in obesity, type 2 diabetes mellitus and cardiovascular diseases
Cinkajzlová, A., Mráz, M., & Haluzík, M. (2021) · Journal of Endocrinology · doi:10.1530/joe-21-0159 · Cited by 51
Metabolic alterations accompanying oncogene-induced senescence
Aird, K. M., & Zhang, R. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.963481 · Cited by 39
“For instance, loss of p53 can suppress OIS in some contexts.(10,31,32) p53 is known to transcriptionally repress glucose transporters (GLUT-1, GLUT-3, GLUT-4) and a number of glycolytic enzymes.”
BackgroundLin, C., Li, H., Liu, J., Hu, Q., Zhang, S., Zhang, N., Liu, L., Dai, Y., Cao, D., Li, X., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0562-8 · Cited by 45
The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer
M�ndez-S�nchez, N., Valencia-Rodríguez, A., Vera-Barajas, A., Abenavoli, L., Scarpellini, E., & Rodríguez, G. P. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2019.29 · Cited by 46
“Interestingly, senescent cells develop a secretory proinflammatory profile known as senescence-associated secretory phenotype (SASP)[79].”
BackgroundDeregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 48
Selective anti-cancer agents as anti-aging drugs
Blagosklonny, M. V. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.27350 · Cited by 43
“The senescent phenotype is characterized by a large, flat cell morphology (hypertrophy), cellular hyperfunctions such as hypersecretion and proinflammation, and an increased lysosomal activity and lipid accumulation.(24-33) Senescent cells have increased levels of cyclin D1.”
BackgroundChiba, M., Sasaki, M., Kitamura, S., Ikeda, H., Sato, Y., & Nakanuma, Y. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2011.090175 · Cited by 43
Iwasaki, K., Abarca, C., & Aguayo‐Mazzucato, C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0416 · Cited by 51
Telomeres, Aging and Exercise: Guilty by Association?
Chilton, W., O’Brien, B. J., & Charchar, F. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122573 · Cited by 49
“Shorter mean LTL may reflect an increased burden of senescent cells which are known to create a pro-inflammatory phenotype [314,315].”
BackgroundColorectal cancer-promoting activity of the senescent peritoneal mesothelium
Mikuła‐Pietrasik, J., Sosińska, P., Maksin, K., Kucińska, M., PIOTROWSKA, H., Murias, M., Woźniak, A., Szpurek, D., & Książek, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4932 · Cited by 45
“Also in that model, senescence-dependent EMT was accompanied by decreased expression of E-cadherin and increased expression of vimentin [35].”
BackgroundSunaga, N., Kaira, K., Tomizawa, Y., Shimizu, K., Imai, H., Takahashi, G., Kakegawa, S., Ohtaki, Y., Nagashima, T., Kasahara, N., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.110 · Cited by 50
“Cellular senescence is part of the aging process (Collado et al, 2007; Lopez-Otin et al, 2013), and is accompanied by a senescenceassociated secretory phenotype (SASP) that involves a marked increase in the secretion of proinflammatory cytokines (Coppe et al, 2008).”
BackgroundKajdy, A., Modzelewski, J., Cymbaluk‐Płoska, A., Kwiatkowska, E., Bednarek-Jędrzejek, M., Borowski, D., Stefanska, K. A., Rabijewski, M., Torbè, A., & Kwiatkowski, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084186 · Cited by 46
“The expression of IL-6 and IL-8 has been extensively studied as biomarkers for measuring senescence [27,58].”
BackgroundChen, L., Wu, B., Mo, L., Chen, H., Yin, X., Zhao, Y., Cui, Z., Cui, F., Chen, L., Deng, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58188-5 · Cited by 55
The development of cell senescence.
Da Silva-Álvarez, S., Picallos-Rabina, P., Antelo-Iglesias, L., Triana-Martínez, F., Barreiro-Iglesias, A., Sánchez, L., & Collado, M. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110742 · Cited by 42
Senescence and Immunoregulation in the Tumor Microenvironment
Ruhland, M. K., & Alspach, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.754069 · Cited by 52
Gemcitabine induces cell senescence in human pancreatic cancer cell lines
Song, Y. H., Baba, T., & Mukaida, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.063 · Cited by 46
Deciphering the roles of acyl-CoA-binding proteins in plant cells
Lung, S., & Chye, M. (2015) · PROTOPLASMA · doi:10.1007/s00709-015-0882-6 · Cited by 46
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.